Figure 3
OS in advanced-stage disease, according to tumor stages T2 (n = 7), T3 (n = 46), and T4 (n = 39). Stages T4 versus T3 (P = .03); stages T3 versus T2 (P = .17); stages T4 versus T2 (P = .008); across all stages (P = .01). Note that all patients with T2 (patch/plaque) disease needed to have lymph node or visceral involvement to be staged as advanced-stage disease and thus be included in this analysis.

OS in advanced-stage disease, according to tumor stages T2 (n = 7), T3 (n = 46), and T4 (n = 39). Stages T4 versus T3 (P = .03); stages T3 versus T2 (P = .17); stages T4 versus T2 (P = .008); across all stages (P = .01). Note that all patients with T2 (patch/plaque) disease needed to have lymph node or visceral involvement to be staged as advanced-stage disease and thus be included in this analysis.

Close Modal

or Create an Account

Close Modal
Close Modal